Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
UCB’s 90-year book is a goldmine to discover!
Twitter Feed
-
Alan Lovell, Senior Assosiate, Health Policy and Clinical Evidence @TheEIU_Health revelling the findings of the research about transition toward patient-centred care in nine countries. https://t.co/xc6PF5C9hb
— UCB News (@ucb_news) 21.02.2019 -
We are live today from the Solvay library at the Patient Value Summit to understand what matters the most for patients when navigation their healthcare. #EconPatientValue @EconomistEvents https://t.co/kynSoK5xPl
— UCB News (@ucb_news) 21.02.2019 -
Tomorrow at the Patient Value Summit: - Opening remarks - @TheEIU briefing - Understanding value: Patient first priorities - Best practices and new technologies - The road forward: Creating a patient-centered healthcare paradigm https://t.co/LFRjSk
— UCB News (@ucb_news) 20.02.2019
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. Discove more...
